Metopen

Methotrexate, the active ingredient in Metopen, is an antimetabolite (folate antagonist) presented as a sterile solution for subcutaneous use. It is employed in the management of rheumatoid arthritis, psoriasis, and certain cancers such as acute lymphoblastic leukemia, acting to modulate disease activity and inhibit malignant cell proliferation.

GNH USA supplies Metopen as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, oncology centres, and pharmacies worldwide, ensuring quality and regulatory conformity across markets, and providing reliable logistics for global distribution through established supply chains.

Methotrexate is a folate antagonist used in several immune‑mediated and oncologic conditions. It modulates inflammatory pathways and inhibits rapidly dividing cells, making it effective for chronic autoimmune disorders and certain malignancies.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: decreases skin lesion severity by limiting keratinocyte proliferation. - Acute lymphoblastic leukemia: impedes leukemic cell growth, contributing to remission. - Juvenile idiopathic arthritis: controls joint inflammation and prevents disease progression in pediatric patients.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting. - Fatigue or malaise. - Oral mucosal ulceration (stomatitis). - Mild to moderate liver enzyme elevation. - Transient alopecia. - Decreased blood cell counts (leukopenia, thrombocytopenia).

Serious or Rare Side Effects: - Severe hepatotoxicity or hepatic fibrosis. - Pulmonary toxicity, including interstitial pneumonitis. - Life‑threatening infections due to profound immunosuppression. - Bone marrow aplasia or pancytopenia. - Renal failure from crystal precipitation. - Severe cutaneous reactions such as Stevens‑Johnson syndrome.

Methotrexate requires careful monitoring and specific safety measures to minimize risks.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: schedule periodic LFTs for hepatotoxicity. - Evaluate renal function: check serum creatinine before dose adjustments. - Avoid use in pregnancy: contraindicated due to teratogenic risk. - Educate on infection signs: report fever or respiratory symptoms promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes; some combinations should be avoided while others need close monitoring.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Aminoglycoside antibiotics: potentiate nephrotoxicity. - Live vaccines: heightened risk of severe infection. - High‑dose folic acid supplements: may reduce methotrexate efficacy.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: may increase myelosuppression. - Proton pump inhibitors: can alter methotrexate absorption. - Trimethoprim‑sulfamethoxazole: enhanced hematologic toxicity.